A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment

Depressive Disorder ◽

Serotonin Reuptake ◽

Adjunctive Treatment ◽

Controlled Study ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Efficacy Outcomes From 3 Clinical Trials of Edivoxetine as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

The Journal of Clinical Psychiatry ◽

10.4088/jcp.14m09619 ◽

2016 ◽

Vol 77 (05) ◽

pp. 635-642 ◽

Cited By ~ 5

Author(s):

Susan G. Ball ◽

Margaret B. Ferguson ◽

James M. Martinez ◽

Beth A. Pangallo ◽

E. Serap Monkul Nery ◽

...

Keyword(s):

Clinical Trials ◽

Depressive Disorder ◽

Reuptake Inhibitor ◽

Serotonin Reuptake ◽

Selective Serotonin ◽

Adjunctive Treatment ◽

Major Depressive ◽

A Randomized, Double-Blind Placebo-Controlled Trial of Oral Creatine Monohydrate Augmentation for Enhanced Response to a Selective Serotonin Reuptake Inhibitor in Women With Major Depressive Disorder

American Journal of Psychiatry ◽

10.1176/appi.ajp.2012.12010009 ◽

2012 ◽

Vol 169 (9) ◽

pp. 937-945 ◽

Cited By ~ 62

Author(s):

In Kyoon Lyoo ◽

Sujung Yoon ◽

Tae-Suk Kim ◽

Jaeuk Hwang ◽

Jieun E. Kim ◽

...

Keyword(s):

Depressive Disorder ◽

Reuptake Inhibitor ◽

Serotonin Reuptake ◽

Controlled Trial ◽

Creatine Monohydrate ◽

Major Depressive ◽

Double Blind ◽

Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study

Journal of Psychiatric Research ◽

10.1016/j.jpsychires.2020.05.017 ◽

2020 ◽

Vol 128 ◽

pp. 43-51

Author(s):

Makoto Kamiya ◽

Helene D. Sabia ◽

Julie Marella ◽

Maurizio Fava ◽

Charles B. Nemeroff ◽

...

Keyword(s):

Depressive Disorder ◽

Receptor Antagonist ◽

Adjunctive Treatment ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

V1b Receptor

Long-Term, Open-Label, Safety Study of Edivoxetine as Adjunctive Treatment for Adult Patients with Major Depressive Disorder Who Were Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment in Japan

Open Journal of Psychiatry ◽

10.4236/ojpsych.2015.52022 ◽

2015 ◽

Vol 05 (02) ◽

pp. 186-194

Author(s):

Emel Serap Monkul ◽

Mark Bangs ◽

Keita Asato ◽

Masashi Takahashi ◽

Yasushi Takita ◽

...

Keyword(s):

Depressive Disorder ◽

Serotonin Reuptake ◽

Adjunctive Treatment ◽

Open Label ◽

Major Depressive ◽

Safety Study ◽

Faculty Opinions recommendation of A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954614.793464630 ◽

2012 ◽

Author(s):

Anand Kumar ◽

Olu Ajilore

Keyword(s):

Depressive Disorder ◽

Reuptake Inhibitor ◽

Serotonin Reuptake ◽

Controlled Trial ◽

Creatine Monohydrate ◽

Major Depressive ◽

Double Blind ◽

Statement of Retraction: Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study

International Journal of Psychiatry in Clinical Practice ◽

10.1080/13651501.2021.1950437 ◽

2021 ◽

pp. 1-1

Keyword(s):

Depressive Disorder ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics

The Pharmacogenomics Journal ◽

10.1038/tpj.2012.32 ◽

2012 ◽

Vol 13 (5) ◽

pp. 456-463 ◽

Cited By ~ 42

Author(s):

Y Ji ◽

J M Biernacka ◽

S Hebbring ◽

Y Chai ◽

G D Jenkins ◽

...

Keyword(s):

Depressive Disorder ◽

Functional Genomics ◽

Reuptake Inhibitor ◽

Serotonin Reuptake ◽

Selective Serotonin ◽

Major Depressive ◽

Genome Wide ◽

Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan

Neuropsychiatric Disease and Treatment ◽

10.2147/ndt.s146428 ◽

2018 ◽

Vol Volume 14 ◽

pp. 1261-1272 ◽

Cited By ~ 2

Author(s):

Yoshinori Watanabe ◽

Yuko Asami ◽

Yoko Hirano ◽

Kazuhiko Kuribayashi ◽

Rio Itamura ◽

...

Keyword(s):

Depressive Disorder ◽

Extended Release ◽

Controlled Study ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Subgroup Analyses ◽

Post Hoc

Reboxetine, placebo and paroxetine comparison in patients with major depressive disorder: A double-blind, placebo- and comparator-controlled study

European Neuropsychopharmacology ◽

10.1016/s0924-977x(01)80204-2 ◽

2001 ◽

Vol 11 ◽

pp. S216 ◽

Cited By ~ 2

Author(s):

C.C. Gallen ◽

M.T. Brown

Keyword(s):

Depressive Disorder ◽

Controlled Study ◽

Major Depressive ◽

Double Blind ◽

Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study

American Journal of Psychiatry ◽

10.1176/appi.ajp.2015.15060770 ◽

2016 ◽

Vol 173 (4) ◽

pp. 400-407 ◽

Cited By ~ 71

Author(s):

Trisha Suppes ◽

Robert Silva ◽

Josephine Cucchiaro ◽

Yongcai Mao ◽

Steven Targum ◽

...

Keyword(s):

Depressive Disorder ◽

Controlled Study ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Mixed Features